Trials / Completed
CompletedNCT02160626
Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis
A Randomized, Double-Blind, Vehicle Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 172 (actual)
- Sponsor
- Aclaris Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101 solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle.
Detailed description
The main objective of this study is to evaluate the dose-response relationship of two concentrations of A-101solution when applied to individual seborrheic keratosis (SK) lesions (target lesions) compared with a matching A-101 Solution Vehicle. Each subject will have 4 target lesions on the trunk/extremities. A further objective is to evaluate the safety and efficacy of two concentrations of A-101 solution and its matching vehicle when applied to SK target lesions on the trunk/extremities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | A-101 Vehicle | Placebo control |
| DRUG | A-101 (40) Topical Solution | A-101 (40) Topical Solution - high dose |
| DRUG | A-101 (32.5) Topical Solution | A-101 (32.5) Topical Solution - low dose |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2014-06-11
- Last updated
- 2019-01-03
- Results posted
- 2018-12-07
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02160626. Inclusion in this directory is not an endorsement.